Shares of TRACON Pharmaceuticals surged 36% on Friday after the company announced that complete response was observed in a choriocarcinoma patient treated with its drug candidate TRC105 in combination with Avastin in compassionate use phase II trial at Dana-Farber Cancer Institute.